ArticleJNCI cancer spectrum2023

Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial.

Jonas Saal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.